Oncolytics Biotech (ONCY) Gains from Investment Securities (2010 - 2025)
Oncolytics Biotech (ONCY) posted quarterly Gains from Investment Securities of $764420.0 for Q3 2025, up 555.37% year-over-year from $116640.1 in Q3 2024, and up 440.4% quarter-over-quarter from $141455.6 in Q2 2025.
Oncolytics Biotech (ONCY) Gains from Investment Securities (2010 - 2025) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Gains from Investment Securities for 14 consecutive years, with $764420.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Gains from Investment Securities rose 555.37% year-over-year to $764420.0; the TTM figure through Sep 2025 stood at $803758.0 (up 117.69% YoY), while the FY2025 annual figure was -$153000.0, up 86.91% from the prior year.
- Gains from Investment Securities climbed to $764420.0 in Q3 2025 per ONCY's latest filing, from $141455.6 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $764420.0 in Q3 2025 and bottomed at -$3.6 million in Q4 2023.
- Historically, Gains from Investment Securities has averaged -$214181.0 across 5 years, with a median of -$30593.2 in 2022.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities tumbled 16761.18% — and 2025, when it surged 555.37%.
- Oncolytics Biotech's Gains from Investment Securities stood at -$39194.8 in 2021, then soared by 154.51% to $21364.4 in 2022, then sank by 16761.18% to -$3.6 million in 2023, then soared by 101.83% to $65142.3 in 2024, then soared by 1073.46% to $764420.0 in 2025.
- Business Quant data shows ONCY's Gains from Investment Securities at $764420.0 in Q3 2025, $141455.6 in Q2 2025, and -$167260.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 764,420.02 |
| Sep 30, 2025 | 764,420.02 |
| Jun 30, 2025 | 141,455.65 |
| Jun 30, 2025 | 141,455.65 |
| Mar 31, 2025 | -167,259.95 |
| Mar 31, 2025 | -167,259.95 |
| Dec 31, 2024 | 65,142.27 |
| Dec 31, 2024 | 65,142.27 |
| Sep 30, 2024 | -167,869.23 |
| Sep 30, 2024 | -167,869.23 |
| Jun 30, 2024 | -171,818.03 |
| Jun 30, 2024 | -171,818.03 |
| Mar 31, 2024 | -644,896.38 |
| Mar 31, 2024 | -644,896.38 |
| Dec 31, 2023 | -3.56 Mn |
| Dec 31, 2023 | -3.56 Mn |
| Sep 30, 2023 | -384,154.19 |
| Sep 30, 2023 | -384,154.19 |
| Jun 30, 2023 | 79,656.41 |
| Jun 30, 2023 | 79,656.41 |